Video Library

The chemotherapy and/or radiation given to patients before a stem cell transplant compromise immunity and leave patients vulnerable to infections. This presentation describes major infection risks and effective responses to them. Many thanks to Takeda Pharmaceutical Company whose support, in part, made this presentation possible.

Stem cell transplant recipients have an increased risk of developing sexual problems and infertility after transplant. In men, erectile dysfunction and low testosterone are the most common sexual problems reported, and both are very treatable.

Transplant does not take away a woman’s sexuality but it can cause sexual difficulties after transplant. There are a variety of effective treatments. Good communication between partners is one important ingredient in resolving sexual difficulties after transplant.

COVID-19 can cause serious illness and death. This presentation discusses the the most effective strategies to prevent a COVID infection, and the pros and cons of medications available to treat transplant recipients who do become infected. Many thanks to Takeda Pharmaceutical Company whose support, in part, made this workshop possible.

Stem cell transplants in older patients have, historically, had lower success rates than those in younger patients. This presentation describes several new promising strategies to improve transplant outcomes and survival rates in older patients. Many thanks to Pharmacyclics, an AbbVie Company, and Janssen Biotech, Inc., Jazz Pharmaceuticals and Omeros Corporation, whose support, in part helped make this workshop possible.

Ovarian failure, estrogen deficiency, decreased sex drive, infertility and vaginal graft-versus-host disease are a concern for many women after a stem cell transplant. This presentation discusses what causes these problems and treatment options, particularly for women with vaginal graft-versus-host disease (GVHD).

The way we think and process information can change after transplant, at least in the short-term time. Called cognitive problems, paying attention, concentrating, remembering things and learning new skills can be difficult. This presentation discusses the factors that can cause cognitive problems and strategies to manage them.

Insomnia, which is defined as difficulty falling or staying asleep, is three times higher among transplant recipients than the general population. Cognitive behavioral therapy for insomnia (CBT-I) is a safer a treatment than sleep medications and more effective long-term.

The skin is the most common target of graft-versus-host disease (GVHD), a frequent complication that occurs after a transplant using donor cells. Although most skin changes after transplant are mild or moderate, more severe skin problems are possible.

Approximately 60% of patients with chronic graft-versus-host disease (GVHD) have GVHD in their mouth. Patients, as well as dentists, often confuse oral GVHD with other mouth problems. Seeking treatment from a dentist familiar with chronic GVHD is important. Many thanks to Kadmon, a Sanofi Company. whose support, in part, made this presentation possible.

Medical marijuana offers new options for managing problems arising from cancer treatment. This presentation reviews the potential benefits and risks of cannabis, who is most likely to benefit, and who should avoid using cannabis.

Bone loss is common after transplant and can lead to fractures with severe consequences for transplant recipients. This presentation describes the causes of bone loss and the diagnostic procedures and treatments that can minimize damage and maintain patient quality of life.